Sugi Predict

Sugi Predict / Compounds / SCHEMBL369538

SCHEMBL369538

SCHEMBL369538

[O-][n+]1cccc2cc(Br)ccc21

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 2/20 0.45
▸ ATM Q13315 1/20 0.39
▸ MAPT P10636 2/20 0.37
▸ HTT P42858 2/20 0.37
▸ HSP90AA1 P07900 1/20 0.37
▸ ACHE P22303 3/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ HDAC8 Q9BY41 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ AHR P35869 1/20 0.31
▸ NR4A2 P43354 1/20 0.31
▸ CYP19A1 P11511 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5782822 0.84 CYP2A6 (0.45) CYP2A6ATMMAPTHTTHSP90AA1
SCHEMBL1771699 0.76 ALDH1A1 (0.45) ATMMAPTHTTHSP90AA1ACHE
SCHEMBL1826895 0.76 CYP2A6 (0.45) CYP2A6ATMMAPTHTTHSP90AA1
SCHEMBL3732872 0.76 ATM (0.39) ATMMAPTHTTHSP90AA1ACHE
SCHEMBL2798405 0.76 KDM4E (0.45) CYP2A6ATMMAPTACHEMEN1
SCHEMBL20996058 0.76 ATM (0.39) ATMMAPTHTTHSP90AA1ACHE
SCHEMBL607157 0.76 CYP1A2 (0.45) CYP2A6ATMMAPTHTTHSP90AA1
SCHEMBL3264399 0.76 MEN1 (0.47) ATMMAPTHTTHSP90AA1ACHE
SCHEMBL1285478 0.73 ATM (0.50) CYP2A6ATMACHEMEN1KMT2A
SCHEMBL9531 0.73 ATM (0.48) ATMACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615824-A1 SUBSTITUTED QUINOLONE COMPOUNDS USEFUL AS INHIBITORS OF TLR9 Bristol-Myers Squibb Company (US) 2025-09-17 — — EP disclosed
CN-120152957-A Substituted quinolones useful as TLR9 inhibitors 百时美施贵宝公司 2025-06-13 — — CN disclosed
EP-4547658-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2025-05-07 — — EP disclosed
CN-119325469-A WEE1 degrading compounds and uses thereof 百时美施贵宝公司 2025-01-17 — — CN disclosed
WO-2024102884-A1 SUBSTITUTED QUINOLONE COMPOUNDS USEFUL AS INHIBITORS OF TLR9 BRISTOL-MYERS SQUIBB COMPANY (US) 2024-05-16 — — WO disclosed
CN-117964553-A Method for selectively synthesizing 2-amido quinoline-N-oxide compound from quinoline-N-oxide compound 延安大学 2024-05-03 — — CN disclosed
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2024-02-29 — — US disclosed
EP-4304727-A1 EGFR INHIBITORS Blueprint Medicines Corporation (US) 2024-01-17 — — EP disclosed
WO-2024006881-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-04 — — WO disclosed
WO-2022192431-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2022-09-15 — — WO disclosed
US-20050203101-A1 Benzimidazole quinolinones and uses thereof CHIRON CORPORATION 2005-09-15 — — US disclosed
EP-1539754-A2 BENZIMIDAZOLE QUINOLINONES AND USES THEREOF Chiron Corporation (US) 2005-06-15 — — EP disclosed
WO-2005047244-A2 INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA CHIRON CORPORATION (US) 2005-05-26 — — WO disclosed
WO-2004076451-A1 IMIDAZO[4,5-B]QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS ALTANA PHARMA AG (DE) 2004-09-10 — — WO disclosed
US-20040092535-A1 Benzimidazole quinolinones and uses thereof CHIRON CORPORATION 2004-05-13 — — US disclosed
WO-2004018419-A2 BENZIMIDAZOLE QUINOLINONES AND USES THEREOF CHIRON CORPORATION (US) 2004-03-04 — — WO disclosed
US-20030130505-A1 Bicyclic androgen and progesterone receptor modulator compounds and methods LIGAND PHARMACEUTICALS, INC. 2003-07-10 — — US disclosed
US-6566372-B1 Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer LIGAND PHARMACEUTICALS INCORPORATED 2003-05-20 — — US disclosed
EP-1212303-A2 BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INCORPORATED (US) 2002-06-12 — — EP disclosed
WO-2001016108-A2 BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INCORPORATED (US) 2001-03-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203101-A1 Benzimidazole quinolinones and uses thereof H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, PBRM1 CYP2A6 3756/4885ATM 670/4885MAPT 57/4885
US-20040092535-A1 Benzimidazole quinolinones and uses thereof GAA, ALPI, IL4I1 CYP2A6 498/4885ATM 2759/4885MAPT 711/4885
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof WEE1, WEE2, PPME1 CYP2A6 3665/4885ATM 444/4885MAPT 2871/4885
US-20030130505-A1 Bicyclic androgen and progesterone receptor modulator compounds and methods AR, NR5A1, PGR CYP2A6 164/4885ATM 3215/4885MAPT 4122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.